Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma.
Minghao LiTamara ProdanovLeah MeuterMichiel N KerstensNicole BechmannAleksander PrejbiszHanna RemdeHenri J L M TimmersSvenja NöltingSara TalvacchioAnnika M A BerendsStephanie M J FliednerMercedes RobledoJacques W M LendersKarel PacakGraeme EisenhoferChristina PamporakiPublished in: The Journal of clinical endocrinology and metabolism (2022)
Patients with sporadic PPGL require long term follow-up, as supported by the 14.7% prevalence of recurrent disease, including recurrences at more than 10 years after first diagnosis. The nature of follow-up could be individualized according to tumor size, location and biochemical phenotype.